These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 6816332)

  • 1. Effects of prostaglandin E1 on microvascular haemodynamics in progressive systemic sclerosis.
    Martin MF; Tooke JE
    Br Med J (Clin Res Ed); 1982 Dec; 285(6356):1688-90. PubMed ID: 6816332
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hemodynamics in nailfold capillaries of patients with systemic scleroderma: synchronous measurements of capillary blood pressure and red blood cell velocity.
    Hahn M; Heubach T; Steins A; Jünger M
    J Invest Dermatol; 1998 Jun; 110(6):982-5. PubMed ID: 9620310
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of local temperature versus sympathetic tone on digital perfusion in Raynaud's phenomenon.
    Engelhart M; Seibold JR
    Angiology; 1990 Sep; 41(9 Pt 1):715-23. PubMed ID: 2221472
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of vasospastic disease with prostaglandin E1.
    Clifford PC; Martin MF; Sheddon EJ; Kirby JD; Baird RN; Dieppe PA
    Br Med J; 1980 Oct; 281(6247):1031-4. PubMed ID: 7427564
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prostaglandin E1 infusions for vascular insufficiency in progressive systemic sclerosis.
    Martin MF; Dowd PM; Ring EF; Cooke ED; Dieppe PA; Kirby JD
    Ann Rheum Dis; 1981 Aug; 40(4):350-4. PubMed ID: 7259326
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy evaluation of prostaglandin E1 against placebo in patients with progressive systemic sclerosis and significant Raynaud's phenomenon.
    Bartolone S; Trifiletti A; De Nuzzo G; Scamardi R; Larosa D; Sottilotta G; Raffa A; Barbera N
    Minerva Cardioangiol; 1999 May; 47(5):137-43. PubMed ID: 10479851
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of prostaglandins I2 and E1 on red cell deformability in patients with Raynaud's phenomenon and systemic sclerosis.
    Dowd PM; Kovacs IB; Bland CJ; Kirby JD
    Br Med J (Clin Res Ed); 1981 Aug; 283(6287):350. PubMed ID: 6788326
    [No Abstract]   [Full Text] [Related]  

  • 8. Effect of ketanserin on Raynaud's phenomenon in progressive systemic sclerosis: a double-blind trial.
    Lukác J; Rovenský J; Tauchmannová H; Zitnan D
    Drugs Exp Clin Res; 1985; 11(9):659-63. PubMed ID: 3916837
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasmapheresis in Raynaud's phenomenon in systemic sclerosis: a microcirculatory study.
    Jacobs MJ; Jörning PJ; Van Rhede van der Kloot EJ; Kitslaar PJ; Lemmens HA; Slaaf DW; Reneman RS
    Int J Microcirc Clin Exp; 1991 Feb; 10(1):1-11. PubMed ID: 2019479
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Raynaud's phenomena: diagnostic and treatment study].
    Priollet P
    Rev Prat; 1998 Oct; 48(15):1659-64. PubMed ID: 9814067
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Digital blood flow and nailfold capillary microscopy in Raynaud's phenomenon.
    Lee P; Sarkozi J; Bookman AA; Keystone EC; Armstrong SK
    J Rheumatol; 1986 Jun; 13(3):564-9. PubMed ID: 3735278
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prostaglandin E1 in severe Raynaud's phenomenon.
    Pardy BJ; Hoare MC; Eastcott HH; Miles CC; Needham TN; Harbourne T; Ellis BW
    Surgery; 1982 Dec; 92(6):953-65. PubMed ID: 6890719
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systemic scleroderma patients have improved skin perfusion after the transdermal application of PGE1 ethyl ester.
    Schlez A; Häfner HM; Kittel M; Braun S; Diehm C; Jünger M
    Vasa; 2003 May; 32(2):83-6. PubMed ID: 12945100
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prostaglandin I2 and E1 and red cell deformability in raynaud's phenomenon and systemic sclerosis.
    Gaylarde PM
    Br Med J (Clin Res Ed); 1981 Dec; 283(6306):1608-9. PubMed ID: 6796187
    [No Abstract]   [Full Text] [Related]  

  • 15. A plethysmographic study of the effect of tetranicotinoylfructose (Bradilan) on digital blood flow in primary and secondary Raynaud's phenomenon.
    Antcliff AC; Bouhoutsos J; Martin P; Morris T
    Angiology; 1974 May; 25(5):312-6. PubMed ID: 4823806
    [No Abstract]   [Full Text] [Related]  

  • 16. Capillary abnormalities, Raynaud's phenomenon, and systemic sclerosis in patients with localized scleroderma.
    Maricq HR
    Arch Dermatol; 1992 May; 128(5):630-2. PubMed ID: 1575525
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prolonged increase in digital blood flow following iloprost infusion in patients with systemic sclerosis.
    Rademaker M; Thomas RH; Provost G; Beacham JA; Cooke ED; Kirby JD
    Postgrad Med J; 1987 Aug; 63(742):617-20. PubMed ID: 2447572
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Standstill of nailfold capillary blood flow during cooling in scleroderma and Raynaud's syndrome.
    Maricq HR; Downey JA; LeRoy EC
    Blood Vessels; 1976; 13(6):338-49. PubMed ID: 1016736
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Parasympathetic activity increases with digital microvascular damage and vascular endothelial growth factor in systemic sclerosis.
    Gigante A; Margiotta D; Navarini L; Liberatori M; Barbano B; Tubani L; Afeltra A; Rosato E
    Clin Exp Rheumatol; 2018; 36 Suppl 113(4):24-27. PubMed ID: 29787366
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Botulinum toxin type A contribution in the treatment of Raynaud's phenomenon due to systemic sclerosis].
    Serri J; Legré R; Veit V; Guardia C; Gay AM
    Ann Chir Plast Esthet; 2013 Dec; 58(6):658-62. PubMed ID: 22204894
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.